Clinical Utility of Positron Emission Mammography

Abstract

Several imaging modalities have been introduced over recent years to better screen for and stage breast cancer. Positron emission mammography (PEM) has been approved by the US Food and Drug Administration and introduced into clinical use as a diagnostic adjunct to mammography and breast ultrasonography. PEM has higher resolution and a more localized field of view than positron emission tomography–computed tomography and can be performed on patients to stage a newly diagnosed malignancy. Review of mammograms together with magnetic resonance or PEM images improves detection of disease.